



DRESNER PARTNERS
INVESTMENT BANKING

Healthcare Services

Quarterly M&A Market Update

Q3 2025

*“We’re not just investment bankers —
we’re strategic partners who understand
how to maximize value and find the right
buyer, partner, or investor”*

Healthcare Services Overview

Q3 2025 Market Commentary

Key Takeaways

➤ General Summary:

- ✓ Healthcare services M&A remains active despite a tougher macro backdrop
- ✓ Deal volume in Q3 2025 showed a moderate increase and buyer appetite continues to be strong, particularly for scalable platforms
- ✓ Valuations have normalized from peak 2021–2022 levels but remain healthy for businesses with recurring revenue and defensible positioning
- ✓ Private equity is emphasizing subsectors with operating leverage (Behavioral, select Specialty PPMs (especially Dental), Home-Based Care, and HCIT/RCM)
- ✓ Diligence expectations have risen — clean financials and clarity around earnings quality are now determining both pricing and pace

➤ Subsector Activity:

- ✓ PPMs (especially Dental), Behavioral Health, and Home Health remain the most active subsectors in terms of both PE-backed platforms and transaction count
- ✓ In addition, we have seen increased activity in CROs, Medical Spas, and Healthcare Staffing
- ✓ These segments continue to attract capital due to scalable operations, recurring revenue models, and strong growth runways

➤ Geographic Distribution:

- ✓ PE-backed headquarters are most concentrated in TX, FL, CA, and the Northeast — consistent with population centers, healthcare demand, and established provider ecosystems
- ✓ Regional fragmentation continues to present roll-up opportunities for both mid-market and large-cap sponsors

➤ Publicly-Traded Valuation Multiples:

- ✓ High-multiple sectors (CROs, CMOs, PPMs) highlight investor preference for specialized, high-margin niches
- ✓ Healthcare Staffing, Clinical Labs, and Long-Term Care remain highly active but with moderate multiples, reflecting market maturity and saturation

Healthcare Services Overview

Q3 2025 Market Commentary (cont.)

Key Takeaways

- **What This Means for Founders and Operators:**
 - ✓ Buyers are paying premiums for scale, revenue visibility, and infrastructure that can support add-ons
 - ✓ Processes are moving fastest when the financial story is clean and defensible
 - ✓ Regional density continues to be a meaningful differentiator in platform value
 - ✓ Strong appetite from private equity remains — but structure now varies based on quality of earnings
 - ✓ If planning a transaction in the next 12–24 months, early preparation materially improves valuation, speed, and certainty to close

What's Driving Valuation Right Now

What Buyers Are Prioritizing

- Earnings quality and margin visibility
- Durable payor mix and compliance infrastructure
- Scalable staffing / provider throughput
- Tech enablement that protects or enhances EBITDA
- Regional density and platform “fit”

Where Buyers Are Hesitating

- Inconsistent AR / working capital timing
- Add-backs unlikely to survive diligence
- Wide performance gaps between locations
- Heavy founder dependency


Competition is strongest for businesses with clarity, not just growth. The more diligence-ready the story, the stronger the pricing and structure

If you're considering a transaction within the next 12–24 months, the window remains favorable — especially if your business offers scale, tech enablement, and/or clinical differentiation

Healthcare Services Transaction Volume

M&A Deal Volume for PE-Backed Platform Investments Up in Q3 2025

Quarterly U.S. PE-Backed Healthcare Services Platform Investments




Source: S&P Capital IQ, Proprietary Research

Subsectors With Most Active M&A Deal Flow

Number of Platform Transactions by Subsector

Quarterly U.S. PE-Backed Healthcare Services Platform Investments by Subsector




Selected subsectors with multiple transactions

Source: S&P Capital IQ, Proprietary Research

Healthcare Services U.S. PE-Backed Companies

U.S. Private Equity-Backed Companies Operating as of the end of Q3 2025

Subsector Overview



Dental PPM transactions remain the most active subsector


Selected subsectors with multiple transactions

Source: S&P Capital IQ, Proprietary Research

Healthcare Services U.S. PE-Backed Companies

U.S. Private Equity-Backed Companies Operating as of the end of Q3 2025 (cont.)

Subsector Overview (cont.)




Dental PPM transactions remain the most active subsector

Healthcare Services U.S. PE-Backed Companies

U.S. Private Equity-Backed Companies Operating as of the end of Q3 2025 (cont.)

Subsector Overview (cont.)




Dental PPM transactions remain the most active subsector


Healthcare Services U.S. PE-Backed Companies

U.S. Private Equity-Backed Companies Operating as of the end of Q3 2025 (cont.)


Selected Subsector Overview



PPM Total 393



Behavioral Total 195




CMO Total 115

Healthcare Services Geographic Distribution

U.S. Private Equity-Backed Companies Operating as of the end of Q3 2025

Corporate Headquarters Map



Source: S&P Capital IQ, Proprietary Research

Healthcare Services Publicly-Traded Comps

Public Multiples: CROs, CMOs, and Long-Term Care Lead the Way

Publicly-Traded Healthcare Services Companies by Subsector

\$ in millions

Subsector	Count	Market Cap.	Ent. Value	Revenues	EBITDA	EV/Revenue	EV/EBITDA
CRO	7	\$9,214	\$12,192	\$3,607	\$736	2.4x	19.7x
CMO - Packaging	3	13,835	14,235	2,197	794	4.5x	18.0x
Long-Term Care	6	3,284	5,312	2,817	277	2.2x	17.5x
PPM - Primary Care / Multi-Specialty	6	1,232	1,130	2,339	63	0.5x	15.3x
CMO - Devices	7	5,304	6,811	1,756	399	2.7x	15.0x
Clinical Labs	6	8,327	10,301	4,285	1,331	2.8x	14.5x
Rehabilitation	3	7,043	8,471	2,130	690	2.4x	14.1x
Home Health / Hospice	9	2,209	2,523	1,504	269	1.4x	13.8x
Managed Care	18	37,133	40,997	70,488	4,610	1.4x	10.9x
Staffing	3	1,094	1,754	2,656	205	0.6x	10.7x
Behavioral - General	4	3,490	5,197	4,479	342	1.3x	10.1x
Distribution	9	25,495	29,017	104,899	1,721	0.6x	9.8x
Hospitals / LTACs	8	19,310	30,251	16,826	2,961	1.2x	7.8x
Other Subsectors	42	4,914	8,164	10,948	875	1.7x	10.6x
Mean		\$10,135	\$12,597	\$16,495	\$1,091	1.8x	13.4x
Median		\$6,174	\$8,317	\$3,212	\$713	1.6x	13.9x

Data as of September 30, 2025

Public market multiples continue to anchor private valuations, but dispersion is widening — quality and financial clarity are now driving premiums

Source: S&P Capital IQ, Proprietary Research

Note: Excludes companies with market capitalizations under \$10 million, negative multiples, EV/Revenue multiples over 15.0x, and EV/EBITDA multiples over 30.0x

Sale Preparation and Market Outlook

How to Prepare for a Sale (Before Going to Market)

What to Get in Place Early

- Clean revenue recognition and AR aging visibility
- Standardized location / unit-level margin reporting
- Consistent provider productivity and compensation tracking
- Compliance and credentialing documents organized in advance
- Light “pre-QoE” diagnostics to identify issues before a buyer does

Why This Matters

- Reduces diligence friction and time to close
- Protects valuation late in the process
- Builds buyer confidence in durability

Strong outcomes today are less about timing the market and more about being diligence-ready before going to market

Where the Market Is Headed Next

Market Outlook

- The environment continues to favor sellers with scale and clean financials
- Capital remains abundant — gating factor is earnings quality, not interest
- Add-on acquisitions will continue to transact fastest
- High-quality platforms will remain scarce and attract premium bids

What to Expect Over the Next 12–18 Months

- Buyer selectivity will stay high, but competition intensifies for clarity
- Margin durability will drive structure as much as valuation
- If rates ease, scarcity premiums may expand further

The window remains constructive — sellers who prepare early will capture the strongest valuations and deal terms



Dresner Partners

Healthcare Services Coverage

About Dresner Partners

Dresner Partners is an investment bank focused on serving middle-market companies with merger & acquisition advisory, institutional private placements of debt and equity, valuation, and strategic consulting services. We work with clients across a wide range of industries in the U.S. and internationally, delivering thoughtful, senior-level guidance through complex transactions. Our professionals bring deep experience, market insight, and a steadfast commitment to integrity—consistently exceeding client expectations and maximizing long-term value

Why Clients Choose Dresner Partners

- **Sector Specialization:** Deep coverage in healthcare services/HCIT, especially PPMs and clinic-based businesses, as well as medical products
- **Senior-Level Execution:** Managing Directors lead every transaction — no handoff to juniors
- **Proprietary Network:** Relationships with thousands of PE firms, family offices, and strategics
- **Customized Processes:** Tailored approach based on shareholder goals, deal structure, and timing

Healthcare Services Coverage Team

Mitchell Stern
Managing Director,
Head of Healthcare

Brian Schofield
Managing Director

Lawrence Pier
Managing Director

Nicholas Coomer
Vice President

Peter Bremhorst
Associate

James Jin
Associate

Mergers Alliance / Dresner Partners

- Coordinated global partnership of industry-focused bankers in all major geographies
- 300 M&A professionals across 35 offices and 24 countries
- Closed over 1,810 transactions valued at more than \$96 billion since 2010
- Consistently ranked among the Top 20 M&A advisors for mid-market transactions



For inquiries regarding potential transactions, please contact Mitchell Stern at mstern@dresnerco.com

Dresner Partners Has Deep Execution Experience Across Healthcare Verticals



 has been acquired by in partnership with Sell-Side Advisor 	 Contract Research Organization received an equity investment /strategic partnership from Strategic Advisor 	 Home Health (Nursing, Physical Therapy, Behavioral Health) financing provided by Financial Advisor 	 Contract Manufacturer (CMO) of Life Sciences Instruments and Tools provided valuation support of tax and financial reporting purposes Financial Advisor 	 Healthcare and Nurse Staffing/HCT has been acquired by Sell-Side Advisor 	 NovaMed Eyecare, Inc. Ophthalmology Physician Practices and Laser Vision Correction Centers / ASCs Advised in the consolidation and financing of ophthalmology practices Financial Advisor 	 Has sold a portfolio of eight skilled nursing facilities to Sell-Side Advisor 	 Radiology Workflow Solutions has been acquired by Sell-Side Advisor 	 has been acquired by Sell-Side Advisor
 has been acquired by Sell-Side Advisor 	 Temporary Healthcare Staffing has been acquired by Sell-Side Advisor 	 has been acquired by Sell-Side Advisor 	 Long-Term Care (Skilled Nursing Facilities) Divestiture of its Kansas SNFs to Sell-Side Advisor 	 has been acquired by Sell-Side Advisor 	 Distributor of OTC, Health and Beauty Care Products has acquired select assets of Zila Pharmaceuticals, Inc. Buy-Side Advisor 	 has been acquired by Sell-Side Advisor 	 Hospital System divested its Specialty and Home Infusion Pharmacy to Sell-Side Advisor 	 has been acquired by Sell-Side Advisor
 Nephrology Physician Groups and Dialysis Clinics have entered into a joint venture with Sell-Side Advisor 	 On-Site Wellness Clinics has been acquired by Sell-Side Advisor 	 Diagnostic Imaging Centers has been acquired in separate transactions by multiple buyers Sell-Side Advisor 	 has been acquired by Sell-Side Advisor 	 Hospital System divested The Pediatric Place (outpatient rehabilitation) Sell-Side Advisor 	 has been acquired by Sell-Side Advisor 	 has been acquired by Sell-Side Advisor 	 Carle Foundation Hospital Hospital System divested its pharmacy business, CarleRX Express, to Sell-Side Advisor 	 has been acquired by Sell-Side Advisor
 has been acquired by Sell-Side Advisor 	 13 Dialysis Centers has been acquired by Sell-Side Advisor 	 has merged with Sell-Side Advisor 	 has been acquired by Sell-Side Advisor 	 has been acquired by Sell-Side Advisor 	 Fertility Testing Laboratories and Services has been acquired by Sell-Side Advisor 	 Hemodialysis and Peritoneal Dialysis Centers has been acquired by Sell-Side Advisory and Fairness Opinion 	 has been acquired by Sell-Side Advisor 	 Services to Neuroscience-Focused Inpatient Facilities and Physician Practices Advised on divestiture of neurologic and orthopedic hospital of NorthShore University Health System Sell-Side Advisor

Next Steps

We partner with high-growth healthcare businesses to deliver premium outcomes—through deep domain expertise, senior-level execution, and extensive investor relationships.

Thinking about a transaction in the next 12–24 Months?

Whether you're:

- **A founder/operator exploring exit options**
- **A private equity firm or family office evaluating a potential liquidity event**
- **A strategic buyer seeking proprietary deal flow**

Let's start a conversation!

For inquiries regarding potential transactions, please contact Mitchell Stern at mstern@dresnerco.com

Disclosures and Disclaimers

The information and views contained in this content have been prepared in part by Dresner Partners. The content does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate any investment or potential transaction. This content is not a research report, as such term is defined by applicable law and regulations, and is provided for informational purposes only. Any and all information, including estimates, projections and other forward-looking statements, presented in this document may involve various assumptions and significant elements of subjective judgment and analysis that may or may not be correct. Dresner Partners has not independently verified, and neither Dresner Partners nor any other person will independently verify, any of the information, estimates, projections or forward-looking statements contained herein or the assumptions on which they are based. The information contained in this document is made as of the date hereof unless stated otherwise. Dresner Partners does not expect to update or otherwise revise this document nor provide any additional information, nor correct any inaccuracies herein which may become apparent.

This content is intended for institutional use only and should not be relied upon by retail investors or members of the general public. The information contained herein is believed by Dresner Partners to be reliable but Dresner Partners makes no representation or warranty as to the accuracy or completeness of such information, and information contained herein that is based on material prepared by others may involve significant elements of subjective judgment and analysis which may or may not be correct. Opinions, estimates and projections contained herein constitute Dresner Partners' judgment and are subject to change without notice.

This content is not to be construed as investment advice, an offer to buy or sell, or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular transaction, nor shall this form the basis of any contract. It does not constitute and should not be construed as an endorsement or recommendation of any entities' products or services.

No part of this material may be copied or duplicated in any form or by any means, or redistributed, without Dresner Partners' prior written consent.

